March 21, 2024 – NCH Rooney Heart Institute announces a breakthrough treatment for patients with valvular heart disease. The surgery was performed by a highly specialized team led by Robert J. Kubedu, M.D., a Harvard-trained interventional cardiologist and director of the NCH Rooney Heart Institute; This is the first transcatheter tricuspid valve replacement performed in the United States. He is one of the first few products in the country after being recently approved by the US Food and Drug Administration (FDA).

First Transcatheter Tricuspid Valve Replacement in Florida – Doctor Holds Device

Tricuspid valve disease is highly prevalent, affecting thousands of Americans with heart disease. This condition usually manifests as valve dysfunction and, in severe cases, can lead to congestive heart failure and poor prognosis. Until recently, treatment options for tricuspid valve disease were limited to drugs aimed solely at symptom relief. The introduction of a minimally invasive transcatheter approach to replacing the tricuspid valve represents a major advance for the thousands of patients suffering from this harmful condition.

The new tricuspid valve is known as the “Evoque” valve and is manufactured by Edwards Lifesciences. The self-expanding prosthetic valve is made from bovine pericardial tissue and is effectively delivered into the heart through a catheter inserted in the groin and manipulated antegrade. throughout the venous circulation. Once in place, the valve is carefully deployed to replace the function of the damaged tricuspid valve. The surgery takes about two hours, and most patients recover quickly and can be discharged from the hospital within two to three days.

First Transcatheter Tricuspid Valve Replacement in Florida – Surgical Imaging

“This significant achievement is not only an important milestone for our patients and our organization, but also underscores our comprehensive commitment to innovation and clinical excellence,” said Dr. Cubeddu. . “As a center of excellence in valvular heart disease, we are most proud and committed to providing patients with a wide range of innovative solutions with early access to breakthrough treatments. The Evoque system is no exception, allowing us to assess and treat more patients with valvular heart disease.”

Naples Comprehensive Health (NCH) remains at the forefront of cardiac care through innovation and research, continually striving to ensure patients have access to the latest advances. The successful completion of the first transcatheter tricuspid valve replacement in Florida further solidifies NCH’s position as a leader in cardiovascular care nationwide.

NCH ​​is one of America’s 100 Best Hospitals for the third year in a row, according to Healthgrades. This accomplishment places NCH in the top 2% of hospitals in the nation for overall clinical performance and will be named one of America’s top 50 hospitals for surgical care in 2024.

For more information about transcatheter tricuspid valve replacement and other cardiovascular services offered at NCH Rooney Heart Institute, please visit www.nchmd.org.

About NCH

NCH ​​(Naples Comprehensive Health) is a locally operated nonprofit organization and advanced community health system.^TM Located in Naples, Florida. The system includes more than just his two hospitals (called NCH Baker Hospital and NCH North Hospital) with a total of 713 beds. NCH ​​is a coalition of 775 physicians and medical facilities in dozens of locations across Southwest Florida, providing nationally recognized quality health care to our communities. Our mission is to help everyone live longer, happier, and healthier lives. For more information, please visit www.NCHmd.org.

Post views: 40